Tirzepatide is a 39-amino acid synthetic peptide that mimics native gastric inhibitory polypeptide (GIP) while simultaneously binding to the glucagon-like peptide-1 (GLP-1) receptor. Its structure includes a C20 fatty diacid moiety attached via a hydrophilic linker at the position 20 lysine residue. This distinct structural modification facilitates strong binding to serum albumin, drastically delaying proteolytic degradation and extending the compound’s half-life for prolonged observational studies.

Current laboratory research focuses on its dual-agonist mechanism, which demonstrates a synergistic effect on glucose-dependent insulin secretion, gastric emptying, and lipid metabolism. In-vitro and animal models utilize Tirzepatide to investigate its impact on pancreatic beta-cell function, central nervous system appetite regulation, and broader metabolic flexibility compared to single GLP-1 receptor agonists.